...

According to the TCGA page on Prostate AdenocarcinomaOvarian serous cystadenocarcinoma, researchers hope to make the following types of discoveries with this data:TCGA researchers have:

• Confirmed that mutations in gene TP53 are present in more than 96 percent of ovarian cases. The TP53 gene encodes a tumor suppressor protein that normally prevents cancer development.
• Analyzed gene expression patterns and found signatures that correlate with poor or better survival. Patients whose tumors showed a gene expression pattern associated with poor survival lived a period 23 percent shorter than patients without that signature.
• Affirmed the existence of four distinct subtypes of ovarian cancer through examination of RNA transcription and DNA methylation patterns.
• Substantiated observations that patients with mutations in their BRCA1 and BRCA2 genes have better odds of survival than patients without mutations in those genes. Approximately 21 percent of tumor cases in this study exhibited BRCA1 and BRCA2 mutations.
• Identified therapeutic opportunities by searching for existing drugs that might correct a genomic error that causes a patient's ovarian cancer. The search yielded 68 genes that could be targeted by existing Food and Drug Administration-approved or experimental therapeutic compounds.
• Analyze correlation between Gleason score and other tumor characteristics to better define aggressiveness
• Examine samples from majority populations and compare to underrepresented populations, such as African Americans who have the highest incidence rate of prostate cancer
• Integrate the genomic information with the proteomic data

Research and Publications

...